Speaker: Zonghai Li
Title: Treatment of Solid Tumor with Chimeric Antigen Receptor-engineered T Cells: Current Status and Future Prospectives
Chimeric antigen receptors (CAR) are artificial recombinant receptors that generally combine the antigen-recognition domain of a monoclonal antibody with the T cell activation domains. Recent years, great success has already been achieved in the clinical trials on CD19-specific CAR T cell therapy for B cell leukemia. Nevertheless, solid tumors remain to be a big challenge for CAR T therapy. In this review, the preclinical and clinical studies on the treatment of solid tumors with CAR-T cells will be summarized. The major hurdles for the success of CAR-T and novel strategies to address these hurdles will also be described and discussed.